Neurogene, Inc. - Common Stock NGNE 深 滬
等待開盤 10-28 09:30:00 美东时间
32.06
+2.170
+7.26%
華盛通- 最 高33.00
- 今 開29.89
- 成交量 83.86万股
- 最 低 29.42
- 昨 收 29.89
- 總市值 4.58亿
- 52周最高 74.49
- 市盈率 靜 --
- 換手率 5.88%
- 52周最低 6.875
- 委 比 -88.22%
- 總股本 1427.19万
- 歷史最高 362.60
- 量 比 6.61
- 振 幅 11.98%
- 歷史最低 6.875
- 每 手 1
- 風險率 9.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多正极材料周报丨蔚蓝锂芯拟增资格林美印尼项目！又一材料公司破产重整！
（来源：我的电池网） 【编者按】正极材料周报，系电池网（微号：mybattery）与国内知名企业容百控股下辖公司——容百科技（微号：Ronbay6880...
10-20 16:12
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 81.2% to $3....
10-10 01:06
Neurogene Completes Discussions With FDA On Embolden Trial, Plans To Initiate Dosing In Q4 2025 Across 13 Rett Syndrome Sites
Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollmentNew preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV
10-09 19:08
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
10-07 23:19
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
Neurogene Inc. Reports Increased Losses Amid R&D Focus
Neurogene Inc. ( ($NGNE) ) has released its Q2 earnings. Here is a breakdown of...
08-12 12:19
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
An announcement from Neurogene ( ($NGNE) ) is now available. Neurogene Inc. ann...
08-12 07:07
Neurogene GAAP EPS of -$1.05
Neurogene press release (NASDAQ:NGNE): Q2 GAAP EPS of -$1.05. Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 milli...
08-12 04:50
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
08-11 20:45
